Can-Fite BioPharma and the National Institutes of Health (NIH) Have Applied for a Patent to Treat Uveitis – a Sight-Threatening Disease

PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE (TASE:CFBI) and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands. Uveitis is the third ophthalmology indication being pursued by Can-Fite, in addition to Dry Eye Syndrome and Glaucoma. Can-Fite successfully concluded a Phase II clinical study in patients with dry eye syndrome recently, and is currently conducting a Phase II clinical trial in patients with Glaucoma or Ocular Hypertension.